ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,988 GBX | -0.32% |
|
+9.52% | +13.09% |
| 26/04 | ASTRAZENECA : DZ Bank sticks Neutral | ZD |
| 26/04 | ASTRAZENECA : UBS keeps a Sell rating | ZD |
| Sales 2024 * | 51.18B 4,268B | Sales 2025 * | 54.76B 4,566B | Capitalization | 231B 19,300B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 710B | Net income 2025 * | 10.2B 850B | EV / Sales 2024 * | 4.91 x |
| Net Debt 2024 * | 19.9B 1,659B | Net Debt 2025 * | 13.44B 1,121B | EV / Sales 2025 * | 4.47 x |
| P/E ratio 2024 * |
27.2
x | P/E ratio 2025 * |
22.9
x | Employees | 89,900 |
| Yield 2024 * |
2.09% | Yield 2025 * |
2.18% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.32% | ||
| 1 week | +9.52% | ||
| Current month | +12.27% | ||
| 1 month | +11.60% | ||
| 3 months | +13.67% | ||
| 6 months | +18.41% | ||
| Current year | +13.09% |
1 week
11 004.00
12 144.00
1 month
10 417.6112 144.00
Current year
9 461.0012 144.00
1 year
9 461.0012 186.00
3 years
7 392.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01/13/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +13.43% | ||
| 5.17% | 18 M€ | +3.79% | - | |
| 4.89% | 776 M€ | +9.34% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 11,988 | -0.32% | 2,360,261 |
| 25/24/25 | 12,026 | +5.94% | 4,952,967 |
| 24/24/24 | 11,352 | +0.75% | 3,596,131 |
| 23/24/23 | 11,268 | +0.16% | 3,561,073 |
| 22/24/22 | 11,250 | +2.78% | 3,448,159 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
29/04/2024
- Roadshow - Day 1
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.4
USD
Spread / Average Target
+10.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.09% | 231B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- AZN Stock
